Testing several study drugs for a brain tumor called glioblastoma
Official title: INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This study is testing several drugs to see if they may help treat glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary.
Read our full plain-language summary
What the trial team says
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently closed to accrual) * QBS10072S
Key facts
- Registry number
- NCT02977780
- Stage of testing
- Phase 2
- Conditions studied
- Glioblastoma
Where it is running
This trial lists 12 sites.
-
Alabama
- University of Alabama at Birmingham (Birmingham)
-
Massachusetts
- Massachusetts General Hospital (Boston)
- Dana Farber Cancer Institute (Boston)
-
Minnesota
- Mayo Clinic (Rochester)
-
New York
- Columbia University Medical Center (New York)
- Memorial Sloan Kettering Cancer Center (New York)
-
Ohio
- Cleveland Clinic (Cleveland)
-
Pennsylvania
- University of Pittsburgh Medical Center (Pittsburgh)
-
Rhode Island
- Lifespan / Rhode Island Hospital (Providence)
-
Texas
- UT MD Anderson Cancer Center (Houston)
-
Utah
- Huntsman Cancer Institute (Salt Lake City)
-
Virginia
- University of Virginia Health System (Charlottesville)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.